RIGEL PHARMACEUTICALS, INC. (RIGL)

Every figure this model derived for RIGL, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2022-12-31
cash 95,329,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 185,529,000 AssetsCurrent 2026-06-30
current liabilities 95,586,000 LiabilitiesCurrent 2026-06-30
equity 425,422,000 StockholdersEquity 2026-06-30
interest expense 8,197,000 InterestPaidNet 2026-06-30
ocf 79,389,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 276,785,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 16,411,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up RIGL on one particular measure came for.

RatioValue
cash operating margin38.34
current ratio1.97
current ratio reported1.94
deferred revenue growth0.0
dilution pct6.52
ebit yoy-16.77
fcf margin28.68
growth cv1.22
interest cover10.62
operating margin31.45
owner earnings margin22.75
revenue growth3.31
revenue growth per share-3.02
roic18.33
rule of 4034.76
sbc pct revenue5.93

What to be careful about

What this model itself distrusts about RIGL's figures. Written by the derivation as it ran, not added afterwards.